chrisvoncsefalvay/vaers-outcomes huggingface dataset:
HEPATITIS A VACCINE GIVEN ON 8-25-08 IN LEFT DELTOID.  ON 8-26-08 ITCHY RAISED PAPULAR RASH AROUND INJECTION SIGHT AND LEFT UPPER ARM AND RIGHT SIDE OF FACE BEGAN.  WORSENED BY TIME OFFICE VISIT ON 8-28-08.  GIVEN BENEDRYL AND XYZAL
Pt received the injection and within 10 minutes she started to feel lightheaded and nauseous. She also stated her tongue felt a little tingly and numb.  She was taken into our immunization room and she started out seating then decided she would feel better laying down. We gave her a half of a Benadryl to help with the nausea. She was given cold compresses, water and some ice to suck on. Her blood pressure was taken and was 122/70 mmHg, heart rate was 58 bpm.  She was laying down for approximately 20 minutes, then stated she was feeling better and moved to a sitting position. She was felt she was improving, and after a few minutes of sitting decided she felt well enough to leave. She did state as she was leaving that she has a similar reaction when she gets blood drawn and that she had been nervous about getting the shot.
patint developed a rash on her body from head to toe; This spontaneous report was received from a nurse referring to a 58 year old female patient. The patient's historical drug included mycolog- II. The patient's concurrent conditions included moderate Intellectual development disorder (IDD), down syndrome, high cholesterol, hypothyroid, cardiomegaly, pulmonary regurgitation, bilateral axially lymphadenopathy grad3 3/ 4 sem, fibrocystic breast disease, glaucoma, gastro esophageal reflux disease (GERD), severe C spine disease, dementia, drug hypersensitivity and hypersensitivity (bubble bath). Concomitant therapies included donepezil, memantine, simvastatin, levothyroxine sodium (SYNTHYROID) and timolol maleate. On 05-DEC-2019, the patient was vaccinated with first dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live, recombinant human albumin (rHA) (M-M-R II), lot # S018593 and expiry date 17-JUN-20121, via subcutaneous route in the left deltoid for prophylaxis (reported as "did a rubella titer and patient was not immune so the patient received MMR II") (strength and dose not reported) that was reconstituted with sterile diluent (dose, lot number and expiry date were not reported). On 20-DEC-2019, the patient developed a rash on her body from head to toe after receiving measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live, recombinant human albumin (rHA) (M-M-R II). On 21-DEC-2019, the rash got worse. The patient did not seek medical attention and it was reported that "the patient is seeing physician today". No product quality complaint (PQC) was reported. Action taken with the suspect therapy sterile diluent was unknown. The outcome of rash was reported as not recovered. The causality assessment was not provided.
Supraventricular tachycardia 115-130 heart rate and complete cognitive "Brain fog" Paralysis on the left, piercing pain all over, Metalic taste in mouth, , nausea and vomiting. Tingling, numbness, no feeling in legs, random nerve failures. Hand motor nerve failure. COPD
About an hour after the injection I had pain and burning going down my left side and in the left side of my chest that lasted about 45 min. I was fine for the next 12 hr. Around midnight I started with chills, joint pain body aches and a headache. I woke up around 2 am with a fever.  All day on the 6th I felt horrible with body aches, joint pain and a severe headache. Around 10 pm on the 6th I started again with chills fever chest pain SOB Cough and vomiting (3 episodes throughout the night.) My lungs currently feel like they are on fire and I continue to have chest tightness, joint pain Severe headache and a cough.  I am approximately 56 hr post second vaccination. I had no problems with the first vaccination
pt recvd vax 17NOV93 & 2 hrs following vax pt exp tenderness, soreness under the arm & into neck muscles; No further details were provided;
VAXELIS was administered to 6 patients after product experienced an excursion was not suitable to use.; This non-serious spontaneous safety report was received on 23-FEB-2023, from an HCP. This case is linked to case MCM-004541 (reference number 2023SA055890 and number 01495388).  Due to the nature of the event, the causality between the reported event "VAXELIS was administered to 6 patients after product experienced an excursion was not suitable to use" and Vaxelis was not applicable.  No further information is expected given that there were no adverse events following Vaxelis administration post-excursion.  For reference purposes this case is linked to MCM-004541 (source case), MCM-004562, MCM-004564, MCM-004563, and MCM-004566, due to same reporter.
My daughter took the first dose of the HPV-9 vaccine on April 10, 2017. On April 12, she experienced dizziness. On April 13, her dizziness got worse and she had severe stomach pains, high fever (>103), and headaches. We gave her fever-reducing meds but she still had temperatures of above 101. On April 14, she continued experiencing severe stomach pains, dizziness, and headaches so we took her to the doctor. The doctor's office didn't seem to think her symptoms were due to the vaccine itself because they were too severe and they suggested a virus infection. The doctor told us to give her Motrin to help with the fever. On April 15, she still had dizziness, a moderate temperate and headaches, but the symptoms weren't as severe compared to April 13 or 14. She finally recovered on April 16. Throughout the several days that she was sick, she only exhibited the symptoms mentioned above. As a parent, I disagree highly with the doctor's conclusion that my daughter had a viral infection. She clearly had bad reactions to the vaccine and the doctor's office denied it. We refuse to give her the next dose of this vaccine and need an outlet to voice concerns about this vaccine.
Soreness at injection site after COVID vaccine; This is a spontaneous report received from a contactable consumer (patient). This patient of unknown age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: unknown), single dose via an unspecified route of administration on an unknown date for COVID-19 vaccination. No medical history was reported. Concomitant medications were not reported. On an unknown date, the patient experienced soreness at the injection site after COVID vaccine. The clinical outcome of soreness at the injection site was unknown.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
Information has been received from a physician concerning a 18 month old male who on 08-OCT-2007 was vaccinated in right arm subcutaneously with a dose of VARIVAX (Merck, lot #658378/1122U). Concomitant therapy included an unspecified influenza shot received at the same time of VARIVAX. The physician said that VARIVAX was a vaccine failure: Physician states that the patient's parents mentioned that the child had a rash since 23-APR-2008. The rash was getting better as of the report date. Upon inspection, the physician thought it looked like simple dermatitis; however, it was unilateral but in unilateral dermatome across the chest which lead the physician to believe that the patient experienced shingles. The patient had not been clinically exposed to chicken pox that the physician knew of but he felt that the patient must had been exposed unknowingly and had a subclinical case. Additional information has been requested.
Left herpes zoster with herpes zoster ophthalmicus conjunctivitis. Currently in treatment with valacyclovir 1 gm TID x 14 days
Injection site erythema, injection site swelling - Information has been received from a registered nurse concerning a male patient who was vaccinated with one dose of varicella virus vaccine live (lot 632059/1452J).  Subsequently the patient experienced redness and swelling at the injection site.  It was noted that this did not spread to other parts of the body.  Unspecified medical attention was sought.  Additional information has been requested.
facial twitching; Muscle spasm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 17Apr2021 (Lot number: ER8735, Expiration Date: 31Jul2021) at the age of 60 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Cancer" (unspecified if ongoing); "Thyroid" (unspecified if ongoing). Concomitant medication(s) included: L-THYROXINE [LEVOTHYROXINE SODIUM] taken for thyroid disorder. Vaccination history included: Bnt162b2 (Lot number: EW0150 and Expiration date: 31Jul2021 as dose 1, single), for COVID-19 immunisation. The following information was reported: MUSCLE TWITCHING (non-serious) with onset 18Apr2021, outcome "not recovered", described as "facial twitching"; MUSCLE SPASMS (non-serious) with onset Apr2021, outcome "unknown", described as "Muscle spasm". Therapeutic measures were not taken as a result of muscle spasms.  Additional information: Patient had the second dose of the Pfizer vaccine on the 17Apr2021 and for the past three days patient have been exhibiting facial twitching.  No follow-up attempts are possible. No further information is expected.
Developed hives on legs. Has taken Benedryl, Allegra & Zertex to no relief
THIS PATIENT WAS SUPPOSED TO RECIEVE A DOSE OF ADULT PFIZER, BUT WAS GIVEN UNDILUTED PEDIATRIC PFIZER
Information has been received from a pharmacist concerning her 10 year old daughter who on 14-AUG-2007 was vaccinated IM with the second dose of varicella virus vaccine live (Oka/Merck). There was no concomitant medication. On 14-AUG-2007, the patient experienced pain immediately after vaccination. As of 14-AUG-2007, the patient had not recovered. No further information is available.
Pt vaccinated with DTP/OPV developed fever 101.8, crying followed by body shaking for 3; eyes rolled back few seconds of limpness then returned to crying. Hosp for evaluation, seizure.
Information has been received from a physician concerning a 6-month-old male who on 05-DEC-2006 and 27-FEB-2007 was vaccinated PO with the first and second doses of Rotateq (lot number not available). On 20-APR-2007, approximately 7 weeks after receiving the second dose, the patient experienced intussusception and was hospitalized. The patient had surgery to correct this and has subsequently recovered. There was no product quality complaint involved. The event was considered to be immediately life-threatening by the reporter. Additional information has been requested.  5/25/07 Received vax records from PCP but did not include vax lot numbers.  T/C to PCP office to request info.  5/25/07 received vax records w/lot numbers.  VAERS database updated w/same.  6/18/07 Received hospital medical records which reveal patient experienced vomiting x 4 days & crampy abdominal pain.  Seen in ER where UGI revealed bowel obstruction.  Admitted 4/20-4/24/07.  Air contrast enema confirmed IS but could not reduce.  Taken to OR for exp lap, small resection w/primary anastomosis & appendectomy.  Progressed well & was d/c to home. FINAL DX: Small bowel-small bowel intussusception reduced by exp laparotomy, small bowel resection w/primary anastomosis & appendectomy.
This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (taste buds are gone) and DYSGEUSIA (metallic taste in mouth) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Apr-2021, the patient experienced AGEUSIA (taste buds are gone) and DYSGEUSIA (metallic taste in mouth). At the time of the report, AGEUSIA (taste buds are gone) and DYSGEUSIA (metallic taste in mouth) outcome was unknown.            Concomitant product use was not provided by the reporter. Treatment information was not provided.
Information has been received from a nurse practitioner concerning a 23 year old female patient who in May 2008, was vaccinated with a first dose of GARDASIL vaccine (yeast) and approximately on 22-JUL-2008 was vaccinated with a second dose of GARDASIL vaccine (yeast). Concomitant medication was not reported. The nurse practitioner reported that the patient developed a red itchy area at the right wrist the evening she received GARDASIL vaccine (yeast). This occurred after both the first and second doses. Both doses were administered in the right arm. The saw her primary care physician after the first accident and he prescribed VALTREX for her and the symptoms resolved. After the second incident the patient saw the reporting nurse practitioner. No treatment was ordered. The nurse practitioner did perform a blood test for Herpes Simplex Virus 1 that was positive. The patient recovered on an unspecified date. There was no product quality complaint. Additional information has been requested.
Itching/pruritus; Rash on back/Rash spread to arm & legs; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PRURITUS (Itching/pruritus) and RASH (Rash on back/Rash spread to arm & legs) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN), AMLODIPINE BESYLATE, ASCORBIC ACID, CALCIUM, MINERALS NOS, RETINOL, TOCOPHERYL ACETATE, VITAMIN B NOS, VITAMINS NOS, ZINC (CENTRUM SILVER [ASCORBIC ACID;CALCIUM;MINERALS NOS;RETINOL;TOCOPHERYL ACETATE;VITAMIN B NOS;VITAMINS NOS;ZINC]) and ROSUVASTATIN CALCIUM (CRESTOR) for an unknown indication.    On 04-Mar-2021 at 2:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced RASH (Rash on back/Rash spread to arm & legs). On an unknown date, the patient experienced PRURITUS (Itching/pruritus). The patient was treated with METHYLPREDNISOLONE (oral) at a dose of 4 milligram. At the time of the report, PRURITUS (Itching/pruritus) and RASH (Rash on back/Rash spread to arm & legs) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information included Methyl prednisone dose pack , Antihistamine and over the counter hydrating lotion. Rash started on his back on 12Mar2021& the patent went to urgent care on 13Mar2021. But they did not tell the cause but prescribed him medication which he took it on 14Mar2021.By this time, the rash spread to arm and legs & the patient suspected that rash is related to the swimming pool he was in and being out in the sun.   Most recent FOLLOW-UP information incorporated above includes: On 08-May-2021: Reporter requested mailing address for form return On 15-Jul-2021: Followup document received on 15-JUL-2021 .Updated concomitant medications .Updated treatment Methyl prednisolone.
Abdominal pain, diahrrea, general ill feeling 12/07. Again 8/08 - Diagnosed Crohn's disease 10/08.  3/9/09 Received PCP vaccine records & medical records of 8/16/07-2/19/2009. FINAL DX: none provided Records reveal patient experienced good health on 8/16/07.  Received HPV #1 & also started on BCP for dysmenorrhea.  RTC 12/10/07 w/abdominal pain x 4-5 days, diarrhea.  Exam revealed decreased bowel sounds & LLQ tenderness.  Dx w/possible colitis.
Information has been received from a physician concerning a 67 year old female who on 16-JUL-2007 was vaccinated with a single dose of Zostavax (Oka/Merck) (lot#658081/0743U).  Concomitant vaccination Pneumovax 23 (MSD) administered at a different site.  On 16-JUL-2007, about five hours after the vaccination, the patient developed a band of erythema at the injection site.  She also complained of redness, pain, and swelling "around her arm but on the back of her arm".  There was no adverse event at the site of the Pneumovax 23 (MSD) vaccine.  Unspecified medical attention was sought.  No other information was provided.  There was no product quality complaint involved.  Additional information has been requested.
pain all over body, chills, head ache, head swimming, falling, high blood pressure, cough, congestion
This spontaneous report was received from a healthcare worker refers to a patient of unknown age who on 03-JUL-2012, was vaccinated with the second dose of GARDASIL (dose, route and lot number not reported) that could have been improperly stored. No adverse events were reported. This is one of several reports from the same source. Additional information is not expected.
Right thigh 6 x 5 cm erythema, increasing 3.5 cm induration.  Warm to touch.  Treatment: Amox 250mg susp, 1 tsp three times a day.
Severe pain to entire left arm radiating to part of left back towards the left side two to three days after injection. Motrin helped very little prompting ER visit. Intermittent severe pain lasted until 12/27/2022 due to medication prescribed from ER Physician. Pain is gone at this time however, numbness and tingling remains throughout my left arm still to this date.
Full left arm pain, 102 degree fever, severe chills, and body aches started at 3:00 AM the day after my second Moderna shot. Chills subsided enough to allow me to sleep in an hour and 30 minutes. Still experiencing mild left arm pain (concentrated to the injection site now), a 101.5 degree fever, mild chills, body aches, and now I have fatigue and a headache. I have not taken any medication.
Pt passed out and was very nauseous. He had just finished playing 18 holes of golf walking in extreme heat (90+ degrees F). Before passing out his face did go white and just looked like he wanted to vomit. He felt fine after laying down and drinking water and getting some sugar in him. Whole event lasted about 15 minutes but pt was passed out for less than 10 seconds.
Information has been received from a 79 year old female consumer with Shingles, Post Herpetic Neuralgia, latex allergy and drug hypersensitivity to acetaminophen (TYLENOL), ibuprofen (MOTRIN), and "(VACTRUM)." A history of "surgery because she fell and hit her head" and "shingles in 2006 for an unknown period of time" who "sometime near the end of 2006" was vaccinated with zoster vaccine live (Oka/Merck). Subsequently the patient did not know if after receiving zoster vaccine live (Oka/Merck) her shingles and PHN got better or worse. Unspecified medical attention was sought with a "spinal physician," there were no lab studies performed. The patient was given pregabalin (LYRICA). she had felt dizzy and fell out of her chair about eight times. At the time of the report the patient had not recovered. There was no product quality complaint involved. No further information is available.
T 100 degrees 24 hrs post vaccine administration. C/O stomach pains with nausea. C/O LUE pain with redness, swelling and warmth at site. 9x9cm-warm and erythema. Tx-ice, cool compress, Tyl, or Motrin.
aches and pains; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 75-year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 06Jan2021 (Lot number: EK4176) at the age of 75 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: PAIN (non-serious), outcome "not recovered", described as "aches and pains".  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021275370 same patient/event, different vaccine dose number
Shingrix subcutaneously instead of IM; This case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 50-year-old female patient who received Herpes zoster (Shingrix) (batch number T29Y2, expiry date 8th April 2023) for prophylaxis.   On 22nd November 2021, the patient received the 1st dose of Shingrix (subcutaneous). On 22nd November 2021, unknown after receiving Shingrix, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route was unknown.  Additional details were provided as follows: The patient received the first dose of Shingrix subcutaneously instead of Intramuscularly, which led to intramuscular formulation administered by other route. The reporter consented to follow up via email.
Patient received vaccine 1/5/14 and called 1/6/14 that lips had swollen. No trouble breathing or any other issues. Ice helped the swelling go down.
About 5 hours after receiving injection, my symptoms were severe headache and intense muscle aches all over body.  Fever.   Symptoms lasted 20 hours.
1 week after vaccination - severe vomitting and diarrhea that lasted several days - 1 week.  Pedidalyte.  Rotateq vaccine given on same day as ComVax - lot 0376U.  We didn't complete anymore rotateq vaccines due to thought that was cause of vomiting and diarrhea
About three months after receiving my second dose, my appendix burst. I had to have emergency surgery due to the ruptured appendix. I was admitted into the Hospital.
Since receiving the course of rabbies vaccinations and immunoglobulin, Patient has developed Central Sleep Apnea and Obstructive sleep apnea.  No history of any sleep problems in the past.  Patient is confused and dizzy on a daily basis.  Patient is in need of a very expensive CPAP machine and his quality of life has drastically decreased.  Is unable to do many tasks once able to.  Is experiencing multiple CNS issues.  Patient is currently unable to afford the machine and is at risk for stroke and/or heart attack.  Patient has been to 2 sleep studies which show evidence of sleep issues.
Child has blisters on upper and lower lip 5 minutes after vaccine administered. Treated w/cold nipple. Observed in office, symptoms improved (blisters decreased) over 30 minutes.
Major head congestion that has lasted for 10 days. Cough that continued for about one week. Chills, general lassitude. No fever.
Swollen arm; Nausea; achiness all over her body; fever; headache; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Swollen arm), NAUSEA (Nausea), MYALGIA (achiness all over her body), PYREXIA (fever) and HEADACHE (headache) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, the patient experienced PERIPHERAL SWELLING (Swollen arm), NAUSEA (Nausea), MYALGIA (achiness all over her body), PYREXIA (fever) and HEADACHE (headache). At the time of the report, PERIPHERAL SWELLING (Swollen arm), NAUSEA (Nausea), MYALGIA (achiness all over her body), PYREXIA (fever) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Pt's states her arm was very swollen.  She had a temp. of 104 degrees and she was in bed for 4 days.  She did not call our office or report this to anyone at the time.  She reported it to our office upon her next visit a month later.
LARGE REDISH AREA ABOUT THE SIZE OF A BASEBALL, NOT RAISED BUT ITCHY AND SLIGHTLY TENDER. LASTED ABOUT 3 DAYS AND DISAPPEARED. DOES NOT SEEM TO BE A PROBLEM CURRENTLY.
Lack of seroconversion-negative titer on 2/16/01. Had Recombivax HB lot 0079J on 5/7/99 and on 6/10/99.